Grace Therapeutics (GRCE) Competitors $3.08 -0.12 (-3.75%) As of 07/25/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. LFVN, IMAB, PBYI, BIOA, CCCC, NVCT, ACOG, MOLN, ENTA, and LYELShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Lifevantage (LFVN), I-Mab (IMAB), Puma Biotechnology (PBYI), BioAge Labs (BIOA), C4 Therapeutics (CCCC), Nuvectis Pharma (NVCT), Alpha Cognition (ACOG), Molecular Partners (MOLN), Enanta Pharmaceuticals (ENTA), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Lifevantage I-Mab Puma Biotechnology BioAge Labs C4 Therapeutics Nuvectis Pharma Alpha Cognition Molecular Partners Enanta Pharmaceuticals Lyell Immunopharma Lifevantage (NASDAQ:LFVN) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Is LFVN or GRCE more profitable? Lifevantage has a net margin of 4.12% compared to Grace Therapeutics' net margin of 0.00%. Lifevantage's return on equity of 34.67% beat Grace Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Lifevantage4.12% 34.67% 15.24% Grace Therapeutics N/A -19.45%-16.99% Do institutionals and insiders believe in LFVN or GRCE? 35.3% of Lifevantage shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 20.7% of Lifevantage shares are owned by insiders. Comparatively, 13.5% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer LFVN or GRCE? Lifevantage presently has a consensus target price of $30.50, indicating a potential upside of 122.47%. Grace Therapeutics has a consensus target price of $12.00, indicating a potential upside of 289.61%. Given Grace Therapeutics' higher probable upside, analysts plainly believe Grace Therapeutics is more favorable than Lifevantage.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lifevantage 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, LFVN or GRCE? Lifevantage has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Which has preferable valuation and earnings, LFVN or GRCE? Lifevantage has higher revenue and earnings than Grace Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Lifevantage, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLifevantage$200.16M0.86$2.94M$0.6919.87Grace TherapeuticsN/AN/A-$9.57M-$0.89-3.46 Does the media refer more to LFVN or GRCE? In the previous week, Lifevantage had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Lifevantage and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.90 beat Lifevantage's score of 0.92 indicating that Grace Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Lifevantage Positive Grace Therapeutics Very Positive SummaryLifevantage beats Grace Therapeutics on 10 of the 13 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.25M$3.07B$5.70B$9.50BDividend YieldN/A2.37%4.60%4.01%P/E Ratio-3.4621.1828.1020.05Price / SalesN/A286.99429.3789.38Price / CashN/A42.7636.2258.56Price / Book0.638.378.665.87Net Income-$9.57M-$55.19M$3.25B$258.55M7 Day Performance-8.33%5.88%4.22%3.73%1 Month Performance4.76%17.33%10.51%11.75%1 Year PerformanceN/A4.42%34.40%18.03% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.5437 of 5 stars$3.08-3.8%$12.00+289.6%N/A$44.25MN/A-3.46N/APositive NewsLFVNLifevantage4.2524 of 5 stars$13.98+0.9%$30.50+118.2%+95.9%$176.01M$200.16M20.26260Positive NewsIMABI-Mab2.8665 of 5 stars$2.12+0.5%$6.00+183.0%+51.8%$173.12M$3.89M0.00380PBYIPuma Biotechnology4.2383 of 5 stars$3.40-1.4%$7.00+105.9%-16.8%$168.74M$230.50M4.42200Upcoming EarningsBIOABioAge LabsN/A$4.70-3.1%N/AN/A$168.50MN/A0.00N/ACCCCC4 Therapeutics2.8525 of 5 stars$2.29-5.4%$12.00+424.0%-64.9%$162.61M$35.58M-1.56150Upcoming EarningsNVCTNuvectis Pharma2.5523 of 5 stars$7.73-1.7%$17.00+119.9%+17.5%$161.48MN/A-6.848ACOGAlpha Cognition1.7278 of 5 stars$9.96-0.3%$20.00+100.8%N/A$159.56MN/A-8.30N/AGap UpMOLNMolecular Partners2.5584 of 5 stars$3.890.0%$12.00+208.6%-31.5%$157.04M$5.65M-2.03180News CoverageENTAEnanta Pharmaceuticals4.0485 of 5 stars$7.34-5.0%$18.00+145.2%-51.7%$156.93M$67.64M-1.62160News CoverageLYELLyell Immunopharma2.5105 of 5 stars$10.41-5.3%$15.00+44.1%-61.9%$154.17M$60K-0.42270News CoverageGap Up Related Companies and Tools Related Companies Lifevantage Alternatives I-Mab Alternatives Puma Biotechnology Alternatives BioAge Labs Alternatives C4 Therapeutics Alternatives Nuvectis Pharma Alternatives Alpha Cognition Alternatives Molecular Partners Alternatives Enanta Pharmaceuticals Alternatives Lyell Immunopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRCE Stock Alerts